News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Meg Monday
April 26, 2026
Study Finds New Treatment Improves Survival in Platinum-Resistant Ovarian Cancer
Meg Monday
April 16, 2026
Daraxonrasib Shows Major Survival Benefit in Metastatic Pancreatic Cancer
Meg Monday
February 5, 2026
Mixing Up Your Exercise Routine May Help You Live Longer, Study Finds
Meg Monday
December 14, 2025
Blood Test May Help Predict Recurrence Risk for Early-Stage HR-Positive, HER2-Negative Breast Cancer
Meg Monday
December 8, 2025
FDA Approves New Blood Test to Help Diagnose High-Grade Prostate Cancer
Meg Monday
October 22, 2025
Trodelvy Shows Significant Benefit in Advanced Triple-Negative Breast Cancer
Meg Monday
October 20, 2025
FDA Approves Libtayo to Help Prevent Return of High-Risk Skin Cancer After Surgery and Radiation
Meg Monday
October 20, 2025
GLP-1 Drugs: A New Clue in Inflammation, Blood Cancer, and Cancer Risk
Meg Monday
October 4, 2025
FDA Approves New Maintenance Treatment for Small Cell Lung Cancer
Meg Monday
September 30, 2025
Blood Test Helps Detect Uterine Cancer Recurrence Earlier Than Scans
Meg Monday
September 24, 2025
New Clinical Data for Daraxonrasib Sets Stage for Global Phase 3 Trial in Metastatic Pancreatic Cancer
Meg Monday
August 26, 2025
Early Blood Test Brings Hope for Detecting Pancreatic Cancer
Meg Monday
1
2
Next Page
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website